Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
We have a wide range of fun and festive designs to choose from. Fund life changing research while spreading joy this Christmas!
This Christmas, your gift can bring us closer to a cure for type 1 diabetes – and every pound you give to our Christmas Appeal will be doubled.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
This event is designed for anyone living with type 1 diabetes who would like to learn more about managing their wellbeing across a variety of contexts.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > News & Events > News
The research, which was co-funded by JDRF, reveals that drugs that target the immune system offer very effective and rapid improvements in stabilising blood sugar levels, often within just three months.
The new JDRF-funded clinical trial called SOPHIST will test a drug to help people with type 1 diabetes and heart failure.
Results from a clinical trial called the PROTECT study show that teplizumab can preserve beta cell function in children and adolescents newly diagnosed with type 1 diabetes.
Children in Northern Ireland are now eligible for a trial screening programme that will identify those at high risk of developing type 1 diabetes in the future.
Thanks to JDRF supporters, we’ve been able to award a £1.3 million grant to King’s College London (KCL) and Steno Diabetes Center Copenhagen to examine how existing drugs, known as SGLT inhibitors, could delay the progression of kidney disease in people living with type 1 diabetes.
A JDRF-supported trial published in the New England Journal of Medicine and presented at the European Association for the Study of Diabetes conference has shown that hybrid closed loop technology helps pregnant women better manage their blood sugars compared to traditional insulin pumps or multiple daily injections.
A clinical trial funded by JDRF suggests that treating children with antiviral drugs when they are first diagnosed with type 1 diabetes could preserve their ability to produce some insulin.
Professor Roman Hovorka, who JDRF has funded since 2006 to develop hybrid closed loop (HCL) technology, has won this year’s EASD-Novo Nordisk Foundation Diabetes Prize for Excellence.
We’ve written a letter to Gillian Keegan MP, Secretary of State for Education, asking her to make exemptions to the Government’s policy on banning mobile phones in schools. We thought you might like to read it.
Our survey has shown that half of people with type 1 diabetes feel that the condition holds them back from physical activity and exercise.
As part of its assessment of hybrid closed loop (HCL), the National Institute for Health and Care Excellence (NICE) has today published an additional consultation on its roll out.
In a JDRF-funded research project in Australia, scientists have turned human pancreatic ductal cells into insulin-producing cells, offering promise for restoring the ability to make insulin in people living with type 1 diabetes.
We have today welcomed our President, Her Majesty The Queen, to University College London (UCL) Institute of Immunity and Transplantation.
Insulet, the company who make Omnipod® products, has announced that their Omnipod® 5 hybrid closed loop (HCL) technology is now available in the UK.
In a study co-funded by JDRF and Diabetes UK, researchers identified 13 genes involved in immune responses, which are activated specifically in people who develop type 1 diabetes at a young age.
We’re pleased to announce the appointment of two new Board Directors, Nadia Swann and Sarah Johnson.
Abbott has announced that its FreeStyle Libre® 3 sensor is now authorised to work with Ypsomed’s mylife™ YpsoPump and CamDiab’s CamAPS FX mobile app.
Genetically engineered beta cells transplanted into mice with type 1 diabetes avoid immune system attack and stabilise blood glucose levels without immunosuppressants.
New research from Kings College London found that African Caribbean people with type 1 diabetes are more likely to develop diabetic retinopathy, which can lead to sight loss.
We’re excited to reveal the first research projects funded by the Type 1 Diabetes Grand Challenge, our partnership with the Steve Morgan Foundation and Diabetes UK.
We are delighted to announce the recipients of our latest Small Grant Awards: Dr Joanna Boldison, Dr Fiona Docherty and Dr Nicholas Thomas.
We are delighted to announce our latest partnership funding opportunity, offered through the Daphne Jackson Trust.
An existing drug, called verapamil slowed the progression of type 1 diabetes in newly diagnosed children and adolescents in a clinical trial funded by JDRF.
Researchers have identified genes that predict the development and progression of diabetic kidney disease, giving us the potential to limit how many people with type 1 experience kidney failure.
Myaware, the only charity in the UK focusing on people affected by myasthenia, is the latest organisation to join Connect Immune Research.
Draft guidance has been published which recommends that the NHS fund hybrid closed loop (HCL) systems, following years of dedicated research and campaigning by JDRF.
A lot has happened over the last 12 months at JDRF, and in the world of type 1 diabetes as a whole. From research breakthroughs to herculean fundraising efforts, here’s a retrospective of everything we’ve been celebrating in 2022.
Daniel Doherty has received the UK Medical Research Council (MRC) Clinical Research Training Fellowship, which will be co-funded by JDRF for the first time.
The Royal Free Charity, which supports the three hospitals in the Royal Free London NHS Foundation Trust, is the newest member of the Connect Immune Research initiative.
The Type 1 Diabetes Grand Challenge – a partnership between the Steve Morgan Foundation, Diabetes UK and JDRF UK– has successfully appointed 17 leading international scientists.
Teplizumab, the world’s first type 1 diabetes disease-modifying drug, has been approved by the USA’s Food and Drug Administration (FDA).
A trial screening programme for type 1 diabetes that could transform the way the condition is identified and managed in its earliest stages, opens for recruitment today.
JDRF’s first in-person annual Gala Ball since 2019 has raised £125,000 for type 1 diabetes research.
Abbott’s FreeStyle Libre systems and Novo Nordisk’s smart insulin pens can now link up virtually to help people with type 1 manage their diabetes more easily.
We are delighted to welcome Terence Lovell as Director of Fundraising and Engagement. Terence has worked in the not-for-profit sector for over 20 years.
Don’t miss out on the latest research, inspiring stories, tech news, upcoming events, and handy information on living well with type 1. Join us now and receive it all straight to your inbox.
Our research is improving the lives of people with type 1 and making strides towards a cure. We’ll keep pushing until we make type 1 diabetes a thing of the past.
